Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444879 | 0.86 | MAPK1 (0.56) | MAPK1KMT2AMEN1ALDH1A1NPC1 | |
| SCHEMBL446627 | 0.75 | MME (0.39) | KMT2AMEN1HSD17B10HDAC3HDAC1 | |
| SCHEMBL24933197 | 0.74 | GRIN2D (0.46) | KMT2AMEN1HSD17B10HDAC3HDAC1 | |
| SCHEMBL24933198 | 0.70 | KMT2A (0.35) | KMT2AMEN1HSD17B10HDAC3HDAC1 | |
| SCHEMBL7166167 | 0.70 | GAA (0.49) | MAPK1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL9465836 | 0.69 | ALDH1A1 (0.52) | MAPK1KMT2AALDH1A1HTTLMNA | |
| SCHEMBL6523 | 0.68 | MME (0.40) | MAPK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL7616452 | 0.68 | CYP1A2 (0.64) | KMT2AHSD17B10ALDH1A1POLBLMNA | |
| SCHEMBL18597899 | 0.68 | GAA (0.41) | MAPK1KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL446074 | 0.67 | L3MBTL1 (0.38) | MAPK1KMT2AMEN1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | MAPK1 1699/4885KMT2A 3951/4885MEN1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.